Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies

References

• Sharun K, Tiwari R, Natesan SK, Yatoo MI, Malik YS, Dhama K. International travel during the COVID-19 pandemic: implications and risks associated with “travel bubbles”. J Travel Med. 2021;27 (8):taaa184. doi:10.1093/jtm/taaa184. PMID: 33009813.
   Web of Science ®Google Scholar
• Darby AC, Hiscox JA. Covid-19: variants and vaccination. Bmj. 2021;n771. [Internet](8):taaa184. doi:10.1093/jtm/taaa184. PMID: 33009813.
   Google Scholar
• Centre for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. CDC; 2021. [accessed 2021 April 4] https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Interest.
   Google Scholar
• Zhou B, Thi Nhu Thao T, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, Pohlmann A, King J, Steiner S, Kelly JN, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592(7852):122–27. doi:10.1038/s41586-021-03361-1.
   PubMed Web of Science ®Google Scholar
• Pereira F. SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin. Gene. 2021 Mar 22;784:145596. doi:10.1016/j.gene.2021.145596. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Sharun K, Tiwari R, Natesan S, Dhama K. SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the one health approach during the ongoing COVID-19 pandemic. Vet Q. 2021;41:50–60. doi:10.1080/01652176.2020.1867776.
   PubMed Web of Science ®Google Scholar
• Davies NG, Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. (80-). 2021;3055:1–16.
   Google Scholar
• Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity. bioRxiv. 2021 Feb 22;432359. doi:10.1101/2021.02.22.432359.
   Google Scholar
• Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372. doi:10.1136/bmj.n579.
   PubMedGoogle Scholar
• Collier DA, De Marco A, Ferreira IATM, Meng B, Datir R, Walls AC, Kemp SSA, Bassi J, Pinto D, Fregni CS, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021. doi:10.1038/s41586-021-03412-7.
   Web of Science ®Google Scholar
• Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529–539.e3. doi:10.1016/j.cell.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Emary WKR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). Lancet. 2021;397(10282):1351–62. doi:10.1016/S0140-6736(21)00628-0.
   PubMed Web of Science ®Google Scholar
• Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, Mohan VK, Abraham P, Panda SBB. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2. J Travel Med. 2021. doi:10.1093/jtm/taab051.
   Web of Science ®Google Scholar
• Pearson CA, Russell TW, Davies NG, Kucharski AJ, Edmunds WJ, Eggo RM; CMMID COVID-19 working group. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. Preprint [Internet]. 2021;50;1–4. https://cmmid.github.io/topics/covid19/sa-novel-variant.html
   Google Scholar
• Wu K, Werner AP, Moliva JI, Koch M, Choi A, Gbe S-J, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv Prepr Serv Biol. [Internet]. 2021. http://www.ncbi.nlm.nih.gov/pubmed/33501442%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7836112.
   Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021. doi:10.1038/s41586-021-03398-2.
   Google Scholar
• Fischer R, Van Doremalen N, Adney D, Yinda C, Port J, Holbrook M, Schulz J, Williamson B, Thomas T, Barbian K, et al. ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 1 disease. bioRxiv. 2021 Mar 11;435000. https://www.biorxiv.org/content/10.1101/2021.03.11.435000v2.
   Google Scholar
• Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021. doi:10.1056/NEJMoa2102214.
   Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Gliwa AS, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv. 2021 Mar 7; 21252647. https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1.
   Google Scholar
• Francisco Martins A, Prehn Zavascki A, Lamb Wink P, Caroline Zempulski Volpato F, Liz Monteiro F, Rosset C, De-Paris F, Krüger RÁ, Luís Barth A. Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalization rates in February 2021, Rio Grande do Sul, Southern Brazil. medRxiv. 2021 Mar 09;21253204. doi:10.1101/2021.03.09.21253204.
   Google Scholar
• Wang P, Wang M, Yu J, Cerutti G, Nair MS, Huang Y, Kwong PD, Shapiro L, Ho DD. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv Prepr Serv Biol. 2021. http://www.ncbi.nlm.nih.gov/pubmed/33688656%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7941628.
   Google Scholar
• Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR, Tada T. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv. 2021 Mar 24;436620. doi:10.1101/2021.03.24.436620.
   Google Scholar
• Annavajhala MK, Mohri H, Zucker JE, Sheng Z, Wang P, Gomez-Simmonds A, Ho DD, Uhlemann A-C. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. medRxiv Prepr Serv Heal Sci. 2021. http://www.ncbi.nlm.nih.gov/pubmed/33655278%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7924303.
   Google Scholar